Key Highlights

  • ARCALYST net product revenue reached USD 286.0 million in the third quarter, compared with USD 180.9 million a year earlier.
  • Net income rose to USD 47.3 million from USD 18.4 million, while operating expenses increased to USD 231.7 million.
  • Full-year ARCALYST revenue guidance rose to USD 1.045 billion to 1.050 billion from USD 980 million to 995 million.
  • Cash, cash equivalents and short-term investments totaled USD 568.8 million at Sept. 30, and the company reported no debt.

ARCALYST Drives the Quarter

Kiniksa Pharmaceuticals (NASDAQ:KNSA) reported third quarter 2026 results on Tuesday, with ARCALYST net product revenue of USD 286.0 million. That compares with USD 180.9 million in the third quarter of 2025, a gain of about 58%. Chairman and Chief Executive Sanj K. Patel credited commercial execution and gains in patient and physician adoption, and said the product is positioned to reach blockbuster status this year.

The release states that about 23% of the 14,000 annual multiple-recurrence patients were actively on ARCALYST at the end of the quarter. On the call, management compared that with 18% at the end of the prior year. More than 5,450 prescribers have written ARCALYST prescriptions for recurrent pericarditis since launch, and average total duration of therapy was about 3 years, in line with the median duration of disease.

Expenses and Profitability

Total operating expenses were USD 231.7 million, up from USD 156.8 million. Cost of goods sold was USD 27.8 million, compared with USD 20.3 million, reflecting higher ARCALYST sales. Collaboration expenses were USD 105.8 million, compared with USD 63.3 million, and are driven primarily by ARCALYST collaboration profitability.

Research and development expenses were USD 32.8 million, compared with USD 24.2 million, on increased KPL-387 clinical activity. Selling, general and administrative expenses were USD 65.4 million, compared with USD 49.1 million, reflecting commercialization investment. Share-based compensation within operating expenses was USD 13.1 million, compared with USD 10.1 million. Operating income was USD 54.2 million, compared with USD 24.0 million, per the call.

Guidance and Balance Sheet

Management raised 2026 ARCALYST net product revenue guidance to USD 1.045 billion to USD 1.050 billion, from USD 980 million to USD 995 million. It guided to 2026 research and development expenses of USD 160 million to USD 170 million and selling, general and administrative expenses of USD 270 million to USD 280 million. The company described its current operating plan as cash flow positive on an annual basis.

At Sept. 30, Kiniksa held USD 568.8 million of cash, cash equivalents and short-term investments and reported no debt. Management said that position supports continued investment in ARCALYST, KPL-387 and KPL-1161.

Pipeline Progress

KPL-387, a monoclonal antibody IL-1 receptor antagonist, is in the pivotal Phase 3 PASTORALE trial in recurrent pericarditis, testing once monthly subcutaneous dosing. The company is enrolling and dosing patients, with data guided for the second half of 2027 and a goal of reaching patients in the 2028 to 2029 timeframe. A supplemental Phase 2 study is evaluating the transition of patients from standard therapies to KPL-387 monotherapy.

KPL-1161, an Fc-modified IL-1 receptor antagonist with a target profile of quarterly subcutaneous dosing, is guided to enter a Phase 1 first-in-human trial by the end of 2026.

Pericarditis Franchise Markers to Follow

Tracking points include the share of the 14,000 multiple-recurrence patients on therapy relative to 23%, prescriber growth against 5,450, and collaboration expenses as a share of revenue. Further items are PASTORALE enrollment, the second half 2027 data timing, and the KPL-1161 Phase 1 start by year end.